Background
==========

Recurrence of hepatocellular carcinoma (HCC) is highly frequent despite curative resection. In a randomized clinical trial, treatment with autologous formalin-fixed tumor vaccine (AFTV) after resection of the monocentric primary HCC reduced the risk of recurrence by 81% (*P* = 0.01) and prolonged median overall survival time (*P* = 0.01) in patients with hepatitis B virus (HBV)-associated HCC \[[@B1]\]. However, we had no clear clinical data on the effect of AFTV on hepatitis C virus (HCV)-related HCC. Here, we report a case of a patient with repeat recurrent HCC that was associated with hepatitis C virus (HCV) who had been unsuccessfully treated 29 times with a variety of conventional methods and endured frequent episodes of recurrent disease. Finally, treatment with a single course of AFTV injection resulted in suppression of potential re-recurrence of HCC for more than 43 months.

Case presentation
=================

A seventy-year-old man visited our clinic on June 10, 2008, and presented us with his twenty-nine-treatment history of HCC over a seven-year period as shown in Table [1](#T1){ref-type="table"}, although the precise doses of chemotherapeutics were not recorded. Before the first treatment, he was hospitalized in 1964 with acute hepatitis and was subsequently found to be an anti-HCV antibody carrier in 1993. Since then, he had been treated with interferon-alpha (IFNa) and monoammonium glycyrrhizinate. However, in October 1993, it was found that he had developed hepatocellular carcinoma (HCC) in S8 of the liver. As therapy for the HCC, multiple conventional treatments had been applied, such as transarterial embolization (TAE), acetic acid injection, radiofrequency ablation (RFA), surgical resection, transcatheter hepatic artery infusion chemotherapy (TAI) with epirubicin, percutaneous ethanol injection therapy (PEIT), and microwave tumor coagulation (MTC). The first surgery was carried out in November 2004 to remove the tumor, but resulted in incomplete resection. During the second surgery in September 2005, 350 g of the left lobe of the liver was removed to resect a portal vein tumor (Vp4). Further chemotherapy with the so-called FAIT protocol (5-fluorouracil (5FU) plus IFNa) \[[@B2]-[@B4]\] was also performed in a clinical trial, and peripheral blood alpha-fetoprotein (AFP) level decreased from 14.2 to 6 ng/ml for six months. However, seven months after the second surgery, the CT image showed recurrent tumors in S7, and the AFP level increased rapidly to 20 ng/ml. Conventional treatments (Table [1](#T1){ref-type="table"}) were ineffective and were followed by repeated regrowths of HCC in S7. Further, AFP level increased from 1,143 to 41,958 ng/ml between July 13 and November 21, 2007 (Figure [1](#F1){ref-type="fig"}). The third aggressive operation was performed together with thoracotomy and partial thoracic diaphragm removal in November 26, 2007, and the tumor was successfully resected (Figure [2](#F2){ref-type="fig"}a). Pathological examination revealed portal vein tumor thrombi (Figure [2](#F2){ref-type="fig"}b). The AFP level rapidly decreased to 7 ng/ml by March 6, 2008, where it maintained level for a month, but slightly increased to 8 ng/ml by May 2, 2008.

###### 

Treatments for recurrent tumors of the present case before the AFTV injection

  **Treatment number**   **Year. Month**   **Treatments**
  ---------------------- ----------------- -----------------------------------------------------------------------------------
  1                      2001.09           TAE to the 5 cm primary tumor in S8
  2                      2002.02-03        TAE to recurrent tumor
  3, 4, 5                2002.11-12        Acetic acid injection, three times; no effect
  6, 7                   2003.09           TAE + RFA; tumor shrinkage
  8                      2004.08           TAE, no effect
  9                      2004.11           First surgical resection; incomplete resection
  10                     2004.12           TAI with epirubicin
  11                     2005.02           TAE for portal vein tumor thrombosis (Vp4)
  12, 13, 14, 15         2005.03-07        Chemotherapy with 5FU and IFNa, preliminary course + three courses; no change
  16                     2005.09           Second surgical resection of portal vein tumor (Vp4)
  17, 18, 19             2006.01-05        Chemotherapy with 5FU and IFNa, three courses
  20                     2006.06           TAE in S7
  21                     2006.10-11        Chemotherapy with 5FU and IFNa, an additional course
  22, 23, 24             2007.02           MTC, PEIT, lipiodol embolization to the recurrent HCC in S7
  25, 26                 2007.03           RFA + PEIT; no effect
  27                     2007.05           Chemotherapy with 5FU and IFNa, an additional course
  28                     2007.08           TAE for 1.2 cm tumor in S7; no effect
  29                     2007.11           Third surgical resection after thoracotomy and partial thoracic diaphragm removal

5FU, 5-fluorouracil; IFNa, interferon-alpha; HCC, hepatocellular carcinoma; MTC, microwave tumor coagulation; PEIT, percutaneous ethanol injection therapy; RFA, radiofrequency ablation; TAE, transarterial embolization; TAI, transcatheter hepatic artery infusion chemotherapy.

The above treatments were carried out at three different institutions prior to presentation at our clinic and were recorded by the patient himself without precise descriptions. After the 29th treatment, a single course of AFTV injection \[[@B5]\] was initiated in July 2008 with no further treatment.

![**Alpha-fetoprotein (AFP) levels after the 11th treatment (TAE).** Autologous formalin-fixed tumor vaccine (AFTV) treatment, which consisted of a single course of vaccine injection, was initiated in July 2008 with no further treatment. 'Chemo' in the figure indicates chemotherapy with 5-fluorouracil (5FU) and IFNa (the so-called FAIT protocol) \[[@B2]-[@B4]\], which was administered as treatments number 12 to 15, 17 to 19, 21, and 27 as shown in Table [1](#T1){ref-type="table"}.](1477-7819-10-144-1){#F1}

![**Re-recurrent tumor in S7 removed during the third resection.** (**a**) The resected 3 cm re-recurrent carcinoma with partial thoracic diaphragm. (**b**) H & E-stained section of the 3 cm re-recurrent carcinoma. Portal vein thrombi were observed.](1477-7819-10-144-2){#F2}

Thereafter, the patient strenuously insisted to be treated with autologous formalin-fixed tumor vaccine (AFTV) at our clinic. AFTV was prepared as previously reported \[[@B5]\] with four paraffin-embedded HCC pieces derived from the third resection. A single course of AFTV therapy consisted of (i) first, a delayed-type hypersensitivity (DTH) test with the fixed HCC fragments but no immunoadjuvant, which was initiated 48 hours before the first AFTV injection, (ii) intradermal injection of AFTV, two weeks apart and up to three times, and (iii) a second DTH test performed two weeks after the last AFTV injection according to the schedule described \[[@B1]\]. The DTH test was negative before the first AFTV injection and became positive (11 × 12.5 mm erythema and 5 × 5 mm induration) after the third AFTV injection as evaluated on August 25, 2008. We found no adverse effects except for small local erythema at the AFTV injection sites. We also observed his blood HCV-RNA level, 5.7 log IU/mL.

Without any further adjuvant therapy, the patient maintained low AFP levels (6 to 8 ng/ml) for more than 43 months (Figure [1](#F1){ref-type="fig"}). The patient remains well with no evidence of metastasis or local recurrence.

Complete suppression of HCC recurrence is known to be difficult to attain with conventional treatment methods. In the present case, eight different therapies (Table [1](#T1){ref-type="table"}) had been applied with no success, since repeated recurrence of the HCC in S7 of the liver occurred before the AFTV therapy. Although the third surgical operation of the recurrent HCC rapidly decreased AFP levels from 41,958 to 7 ng/ml, it was highly likely that the potentially remaining HCC cells were not completely removed, since multiple portal vein tumor thrombi have been observed (Figure [2](#F2){ref-type="fig"}b). Also, HCC recurrence rates in patients of positive HCV-RNA were known very high, such as 55.3% at the third year and 72.2% at the fifth year after surgical resection \[[@B6]\]. In this case, recurrent tumors in S7 were found seven months after the second operation, which had decreased the AFP level down to 6 ng/ml. Therefore, we consider that, after the third operation, AFTV treatment successfully suppressed potential further HCC recurrence in this patient.

Conclusions
===========

The findings from the present case suggest that AFTV treatment suppressed potential further HCC recurrence for more than 43 months after the third resection and that AFTV is a feasible therapy for further large-scale clinical trials for suppression of HCC recurrence that is associated with not only HBV but also HCV after surgical resection.
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